| abstract |
antitumor agent for treating a patient with a malignant tumor that expresses egfr with at least one mutation selected from the group consisting of the exon 18 g719x mutation, exon 18 e709x mutation and exon 21 l861x mutation, where x represents an amino acid residue arbitrary, the anti-tumor agent comprising (s) -n- (4-amino-6-methyl-5- (quinolin-3-yl) -8,9-dihydropyrimido [5,4-b] indolizin-8-yl ) acrylamide or a salt thereof. |